Molecular Autism (Apr 2021)

Shifted phase of EEG cross-frequency coupling in individuals with Phelan-McDermid syndrome

  • Michael. G. Mariscal,
  • Elizabeth Berry-Kravis,
  • Joseph D. Buxbaum,
  • Lauren E. Ethridge,
  • Rajna Filip-Dhima,
  • Jennifer H. Foss-Feig,
  • Alexander Kolevzon,
  • Meera. E. Modi,
  • Matthew W. Mosconi,
  • Charles A. Nelson,
  • Craig M. Powell,
  • Paige M. Siper,
  • Latha Soorya,
  • Andrew Thaliath,
  • Audrey Thurm,
  • Bo Zhang,
  • Mustafa Sahin,
  • April R. Levin,
  • the Developmental Synaptopathies Consortium

DOI
https://doi.org/10.1186/s13229-020-00411-9
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Phelan-McDermid Syndrome (PMS) is a rare condition caused by deletion or mutation of the SHANK3 gene. Individuals with PMS frequently present with intellectual disability, autism spectrum disorder, and other neurodevelopmental challenges. Electroencephalography (EEG) can provide a window into network-level function in PMS. Methods Here, we analyze EEG data collected across multiple sites in individuals with PMS (n = 26) and typically developing individuals (n = 15). We quantify oscillatory power, alpha-gamma phase-amplitude coupling strength, and phase bias, a measure of the phase of cross frequency coupling thought to reflect the balance of feedforward (bottom-up) and feedback (top-down) activity. Results We find individuals with PMS display increased alpha-gamma phase bias (U = 3.841, p < 0.0005), predominantly over posterior electrodes. Most individuals with PMS demonstrate positive overall phase bias while most typically developing individuals demonstrate negative overall phase bias. Among individuals with PMS, strength of alpha-gamma phase-amplitude coupling was associated with Sameness, Ritualistic, and Compulsive behaviors as measured by the Repetitive Behavior Scales-Revised (Beta = 0.545, p = 0.011). Conclusions Increased phase bias suggests potential circuit-level mechanisms underlying phenotype in PMS, offering opportunities for back-translation of findings into animal models and targeting in clinical trials.

Keywords